AboutPricingLoginBook a demo
AboutPricingLoginBook a demo

Resalis Therapeutics

Ownership
Private
Therapeutic Areas
GastroenterologyMetabolic Disorders
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
RNA-based therapiesantisense oligonucleotides

Resalis Therapeutics General Information

Developing RES-010, a first-in-class antisense oligonucleotide targeting miR-22 for obesity and metabolic disorders. Phase1 trial ongoing (2024), with Phase2 planned following Sanofi investment.

Contact Information

Website
https://www.resalistherapeutics.com/
Primary Industry
Biotech
Corporate Office
Turin, n/a
Italy

Drug Pipeline

RES-010
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Resalis Therapeutics's pipeline data

Book a demo

Key Partnerships

{\"partner\":\"Sanofi\",\"type:strategic equity investment\"}, {\"partner:Aalborg University\",\"type:scientific collaboration\"}, {\"partner:Harvard Medical School\",\"type:scientific roots\"}

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Resalis Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Resalis Therapeutics's complete valuation and funding history, request access »

Resalis Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals